Physician profile
Gerald C Dey
NPI 1922020502
$7,401.29
in general payments reported to CMS, 2019-2025
39 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,777 · 2020: $2,382 · 2021: $1,394 · 2022: $48.60 · 2023: $214 · 2024: $329 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,423.74 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,321.67 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.95 | 2019-2021 | |
| Csl Behring | $556.26 | 2019-2021 | |
| Pfizer INC. | $476.51 | 2019-2021 | |
| Insmed, INC. | $450.72 | 2019-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $322.35 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $269.46 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $251.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $225.59 | 2019-2020 | |
| Mylan Specialty L.P. | $177.94 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $176.27 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $153.97 | 2019-2020 | |
| Grifols USA, LLC | $144.54 | 2019-2021 | |
| Abbvie INC. | $85.63 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Dey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.